Is Amgen Stock a Buy? [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
The company has been expanding its business via acquisitions in recent years as it looks to inject some much-needed growth into its top line. But a rising debt load isn't making investors too excited about the business, despite its potential. Below, I'll look at the company's financials, opportunities, risk, and valuation to help assess whether this is a stock worth buying today. Higher revenue and lower earnings ahead On Feb. 6, Amgen reported its year-end results for 2023. Revenue of $28.2 billion rose by 7% on a year-over-year basis. The results included a boost from its recent acquisition of Horizon Therapeutics, which closed in October. But Amgen's top-selling drug of last year, Enbrel, saw its sales decline by 10% in 2023 to $3.7 billion, with the company blaming lower selling prices and inventory levels for the drop in revenue. Down the road, this could be more of an area of concern for investors, because the rheumatoid arthritis treatment may lose patent protection bef
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- What's in the Cards for Amgen (AMGN) This Earnings Season? [Yahoo! Finance]Yahoo! Finance
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY [Yahoo! Finance]Yahoo! Finance
- AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCYPR Newswire
- Biologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033 [Yahoo! Finance]Yahoo! Finance
- Microbial Products Market to Gain $286.53 Billion, by 2033 with 6% CAGR: States The Brainy Insights [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- AMGN's page on the SEC website